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ABSTRACT 
Sphingolipids (SLs) and cholesterol are critical structural components of membrane 
bilayers. Although recent evidence has revealed an emerging role of both lipids in 
signaling pathways, their contribution to cancer development and treatment has been 
largely overlooked. Sphingolipids comprise a family of bioactive lipids with divergent 
roles in numerous cellular processes. In particular, ceramide is the prototype of SLs and 
identified as a cell death effector whose levels increase in response to apoptotic stimuli 
such as ionizing radiation or chemotherapy. In the liver, ceramide/cholesterol 
accumulation contributes to a wide range of pathologies, including the transition from 
steatosis to steatohepatitis, which can further progress to cirrhosis and hepatocellular 
carcinoma (HCC). Moreover, different studies have shown that either pharmacologic 
ceramide accumulation or systemic intravenous administration of liposomal ceramide is 
an effective approach against HCC. In addition, mitochondrial cholesterol trafficking 
has emerged as a novel factor regulating cell death pathways and HCC tumor growth 
and chemoresistance. Due to the poor efficacy of current HCC treatments, 
understanding of the role of ceramide/cholesterol in HCC may open up novel avenues 
for therapy. Here we describe recent evidence indicating that ceramide-generating 
agents and/or pharmacological targeting of sphingolipid/cholesterol metabolism, alone 
or in combination with other chemotherapeutic compounds, may be a promising 
strategy in HCC management. 
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INTRODUCTION  
Bioactive sphingolipids (SLs) comprise a family of lipids with divergent roles in 
numerous cellular processes. For instance, ceramide, sphingosine-1-phosphate (S1P) or 
GD3 ganglioside, exert antagonizing roles in diverse cellular functions such as growth 
arrest, cell proliferation, or apoptosis [1,2,3,4,5]. Ceramide is the prototype of SLs and 
has been the subject of intense scrutiny and research due to its role in controlling 
signaling pathways leading to cell death in response to apoptotic stimuli (e.g. stress, 
death ligands, radiation or chemotherapy) [5,6,7], as well as in the organization of 
specific signaling domains of plasma membrane termed ceramide-rich platforms [8]. 
Cells generate ceramide by different pathways, most predominantly from the de novo 
synthesis from L-serine and palmitoyl-CoA in the ER that requires the concerted action 
of several enzymes. While this pathway is slow and sustained in time, there is another 
fashion whereby cells generate ceramide quickly, and often, transiently, mainly due to 
the breakdown of sphingomyelin upon activation of sphingomyelinases (SMases). Once 
produced, ceramide may target different signaling pathways involved in cell death, thus 
underlying its proapoptotic function [1,2] or can be metabolized to other derivatives 
with divergent functions. While the ceramidase/sphingosine kinase axis generates 
antiapoptotic derivatives (e.g. S1P), the addition of carbohydrates and sialic acid 
residues to ceramide generates complex sphingolipids, such as gangliosides, which 
transmit the proapoptotic function of ceramide depending on its intracellular 
distribution. The synthesis of glucosylceramide to complex glycosphingolipids requires 
the transfer of ceramide from the ER to the Golgi by specific proteins (e.g. CERT) that 
regulate ceramide homeostasis. Since ceramide and gangliosides (e.g. GD3) are 
proapoptotic, the loss or gain of function of CERT may represent another mechanism to 
regulate cell death and cancer development [9].  
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Moreover, cholesterol is an integral component of cellular membranes that plays an 
essential role in maintaining their integrity and function. Although cholesterol 
homeostasis has been the subject of intense research in the context of cardiovascular 
diseases, there is a growing body of evidence pointing to a critical role of cholesterol in 
liver physiopathology, particularly emerging as a key player in chronic liver diseases, 
including steatohepatitis, a prevalent form of liver disease characterized by steatosis, 
inflammation, oxidative stress, hepatocellular death, and fibrosis, which can further 
progress to more advanced states such as cirrhosis and hepatocellular carcinoma (HCC). 
HCC is one of the main causes of cancer-related death that exhibits high resistance to 
current therapy. Alterations in cholesterol metabolism and intracellular trafficking have 
been disclosed as critical factors in HCC biology and therapy, and hence may constitute 
novel targets to improve the current treatment armamentarium for HCC. In the present 
review, we will briefly cover emerging new aspects of the metabolism of ceramide and 
cholesterol in HCC, focusing on novel developments suggesting that targeting these 
lipids may be of relevance as a new therapeutic approach in HCC.  
Ceramide formation from de novo synthesis. 
SLs and their metabolites are major components of biological membranes that in 
addition to the key structural role also act as signaling molecules. This functional 
dichotomy is determined by their structural diversity, as SLs encompass a large group 
of lipids, including sphingosines, ceramides, sphingomyelin, and various 
phosphorylated and glycosylated derivatives. SLs form cellular membranes together 
with glycerolipids and sterols and are distinguished from these other lipids by their 
chemical structures, physical properties, and specialized enzymatic machinery. SLs 
utilize two key lipid building blocks, namely long-chain bases and fatty acids, and use 
serine rather than glycerol as the backbone to which acyl chains are attached. These 
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characteristic core features of sphingolipids, together with their head-group 
modifications, enable them to have unique and essential functions in eukaryotic cells. 
As depicted in Figure 1, ceramide, the prototype of SLs is generated from the 
condensation of serine with palmitoyl-CoA resulting in sphingosine formation followed 
by acylation with fatty acyl CoAs of varied lengths. Ceramide has been the subject of 
intense investigation due to its structural role in membrane bilayers as well as a 
signaling molecule regulating a number of cellular processes, including cell 
proliferation, differentiation, adhesion and cell death [1-4]. 
Consistent with the key structural role of ceramide in membrane bilayers, the de novo 
ceramide synthesis pathway is generally envisioned as a major source of the ceramide 
pool that participates in the maintenance of physico-chemical properties of cell 
membranes. Ceramide synthesis begins on the cytosolic face of the endoplasmic 
reticulum (ER) membrane with the condensation of serine and fatty acid-coenzyme A 
(FA-CoA). This reaction is the rate-limiting step in de novo ceramide synthesis and is 
catalyzed by the enzyme serine palmitoyltransferase (SPT). A reduction step can yield 
key intermediates such as sphingosines or long-chain bases, which can be 
phosphorylated or N-acylated with a second FA-CoA to produce ceramides. Notably, 
these amide-linked acyl chains are often saturated and tend to be longer than those seen 
in glycerolipids. However, ceramide neo-genesis is gaining attention in cellular stress 
response signaling, since enhanced de novo ceramide synthesis occurs in response to 
chemotherapeutic agents [7,10] due to the activation of SPT or the recently cloned 
family of ceramide synthases (CerS1-6) [11,12,13]. Particularly, CerSs [14] are highly 
specific proteins as proven by the special affinity of each CerS for a unique set of fatty 
acid chains (Table 1). Therefore, an increase in a particular CerS may regulate a 
specific ceramide pool that may affect the integrity and function of individual cell 
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compartments, such as lysosomes, endoplasmic reticulum (ER) or mitochondria. 
Moreover, since CerS distribution differs among organs [14], the capacity of each 
individual tissue to withstand apoptotic stimuli may be determined by the characteristic 
mRNA CerS pattern. For instance, in the liver CerS4 and specially CerS2 are highly 
expressed, being mainly responsible for long chain ceramides that are thought to play 
structural roles in cell membranes. However, under certain circumstances hepatic levels 
of CerS5 may be induced, resulting in increased synthesis of C16-ceramide, which 
unlike C18-ceramide, is often considered a proapoptotic ceramide, at least in certain cell 
types [15]. While there is not evidence that HCC-related chemotherapy affect CerSs 
expression and hence hepatic ceramide levels, CerS1 activation has been detected after 
UV irradiation, cisplatin or doxorubicin treatment, contributing to the C18-ceramide-
induced death of colon cancer cells and tumor growth suppression in SCID mice  
[15,16]. Similarly, lymphoma cells treated with cannabinoids displayed CerS3 and 
CerS6 mRNA upregulation, leading to C16, C18 and C24-ceramide accumulation and 
consequent cell death [17]. Moreover, ionizing radiation induced apoptosis in HeLa 
cells through de novo ceramide synthesis by the specific activation of CerS isoforms 2, 
5, and 6 that generate opposing anti- and pro-apoptotic ceramides in mitochondrial 
membranes [18]. These results not only demonstrate the interplay among the CerS 
proteins in a cell type- and subcellular compartment-specific manner, but also illustrate 
the complexity and organ-dependent activation of CerS in response to specific 
proapoptotic stimuli.  
In contrast to the role of de novo ceramide synthesis in regulating extra hepatic tumors, 
the involvement of this particular pathway of ceramide homeostasis in HCC is less 
established. Nevertheless, alterations in de novo ceramide synthesis have been related to 
increases in liver cancer incidence. For instance, exposure to fumonisin B1, the most 
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typical inhibitor of CerS activity, has been reported to induce liver and kidney tumors in 
rodents, and studies in maize-consuming human populations suggest a connection 
between this mycotoxin and the frequency of liver and esophageal cancer in these 
communities [19,20]. In parallel, besides the predominant neural defect, the CerS2-
deficient mice exhibit strongly reduced levels of ceramide species with very long fatty 
acid residues (VLCFC) in the liver and develop HCC at the age of 7-10 months old 
[21,22]. In addition, although none of the current strategies recommended for patients 
with HCC seems to be directly linked to this pathway, de novo ceramide synthesis has 
been shown to participate in stages that regulate and precede HCC development. For 
instance, de novo ceramide synthesis has been recently identified as a critical link 
between the proinflammatory TLR4 receptor and insulin resistance in obesity [23]. 
Given the association of inflammation and insulin insensitivity with HCC and that 
obesity is a risk factor for HCC, targeting the de novo ceramide synthesis as a putative 
pathway regulating HCC biology is an open question that remains to be further 
analyzed.  
Ceramide generation through hydrolysis of  higher sphingolipids 
Breakdown of complex sphingolipids is another effective way of increasing ceramide 
content in cells [1-4] (Figure 2). In particular, sphingomyelin hydrolysis upon 
activation of SMases is considered a mechanism for the rapid  and transient generation 
of ceramide, which then impacts on diverse signaling pathways in response to numerous 
deleterious stimuli, and more importantly, accounts for the critical ceramide pool 
involved in and responsible for many different pathologies [3,24,25,26,27,28]. Although 
several mammalian SMases have been characterized, neutral sphingomyelinase 2 
(NSMase 2, SMPD3) and acid sphingomyelinase (ASMase, SMPD1) are the most 
extensively studied enzymes in ceramide generation, and the most relevant in cell death 
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regulation and pathology. While NSMase-induced ceramide generation has been 
described as a critical lipid in inflammatory diseases and oocyte maturation [29,30], 
ASMase with an optimum pH of 4.5-5.5, has been extensively described as a signaling 
intermediate in cell death pathways, of particular relevance in the progression of liver 
diseases [24,27,28,31]. ASMase catalyzes the formation of ceramide from SM primarily 
within the endo-lysosomal compartment, although it can be secreted extracellularly 
through Golgi trafficking as a secretory ASMase (S-SMase) [3,4]. The dependence on 
Zn2+ for proper function is a cardinal differential feature between both ASMase and the 
secreted form, with the former being Zn2+ independent unlike the secretory enzyme. 
Both isoforms derive from a proinactive form whose proteolytic processing within the C 
terminal leads to the maturation of the endosomal/lysosomal ASMase and the secretory 
form [32]. Consistent with this process, unlike the pro-ASMase form, the mature 
ASMase counterpart (65kDa) is sensitive to the lysosomotropic inhibitor 
desipramine/imipramine [32]. In addition, deficiency of ASMase results in a lysosomal 
storage disorder (Niemann-Pick disease) characterized by accumulation of 
sphingomyelin, with multi-organ consequences. In fact, ASMase knockout mice, 
initially described as animal model of Niemann-Pick A disease, has played a prominent 
role in positioning ASMase as a relevant enzyme mediating cell death induced by a 
variety of stress stimuli and death ligands. Of particular relevance for liver diseases, it 
has been shown that the liver of ASMase knockout mice is resistant to Fas or TNF 
exposure [27,33], ischemia/reperfusion [34], Cu accumulation underlying Wilson 
disease [28] or diet-induced steatohepatitis [31,35], compared to wild type mice, thus 
indicating that the ASMase/Cer pathway is a critical axis in liver pathobiology.  
As depicted in Figure 2, the de novo synthesized ceramide in the ER can be 
transformed into other complex derivatives (e.g. gangliosides, cerebrosides such as 
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glucosylceramide or as galactosylceramide typically found in neural tissue) in the 
Golgi, which in turn serve as an additional source of ceramide production. Besides the 
well known ceramide-sphingomyelin-ceramide relationship, requiring the conversion of 
ceramide into SM via an ER-Golgi cross-talk involving CERT and SM hydrolysis by 
SMases described above, a very interesting mechanism of ceramide generation 
described recently is through the downregulation of sphyngomyelin synthase related 
protein (SMSr), an ER-resident transmembrane protein. Unlike SMS1 and SMS2, SMSr 
does not synthesize SM but instead exhibits a ceramide ethanolamine 
phosphotransferase activity that synthesizes ceramide phosphoethanolamine (CPE). 
Interestingly, downregulation of SMSr by siRNA induces a dramatic increase in 
ceramide and glucosylceramide levels that cannot be accounted for by loss of SMSr’s 
CPE-producing activity [36]. Most intriguingly, SMSr silencing induces the trafficking 
of ceramide to mitochondria leading to cell death [36]. Whether this function of SMSr is 
a general phenomenon present in different cell types needs to be further established. 
Nevertheless, other complex glycosphingolipids (such as gangliosides or cerebrosides) 
may be an additional source of ceramide production. For instance, detachment of sugar 
unit from ganglioside GM3 by Neu3 has been shown to generate plasma membrane 
ceramide in human fibroblasts [37]. Neu3-overexpressing fibroblasts were characterized 
by a reduced proliferation rate and higher basal number of apoptotic cells in comparison 
with wild-type cells. Although, the participation of this additional mechanism of 
ceramide generation by glycosphingolipid hydrolysis has not been clearly established in 
hepatocarcinogenesis, the potential use of activators of these proteins to promote the 
hydrolysis of complex sphingolipids into ceramide may be of interest to increase cancer 
therapy efficacy and deserves further investigation. 
Ceramide catabolism: ceramidases and glucosylceramide synthase. 
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Consistent with the effects described in other cell types, the increase in hepatocellular 
ceramide levels triggers cell death via mechanisms including loss of mitochondrial 
membrane potential and release of proapototic intermembrane mitochondrial proteins 
[38,39,40], activation of JNK [41,42], inhibition of AKT [43] or ceramide-mediated 
dephosphorylation of the BH3-only protein Bad [44]. Interestingly, although ceramide 
is a well-characterized proapoptotic SLs it can be transformed into other nonapoptotic 
derivatives via different mechanisms. Among them, ceramide glycosylation by 
glucosylceramide synthase (GCS) into glucosylceramide (Figure 2), and ceramide 
catabolism to sphingosine 1 phosphate (S1P) after the consecutive action of ceramidases 
and sphingosine kinases are of major relevance in liver pathophysiology. As expected 
from the relative balance between these proapoptotic and antiapoptotic SLs forms, 
targeting these ceramide catabolic pathways may be of therapeutic value to kill tumor 
cells. 
Three ceramidase (CDase) isoforms with distinctive pH optimums, acid, alkaline and 
neutral, have been described [45], being their relative contribution to cell death 
dependent on the stimuli and the cell type studied. Although the neutral CDase has been 
shown to play a protective role against cytokine-induced cell death in mesangial cells 
[46], the acidic CDase in the isoform that has been more clearly involved in the 
regulation of cancer progression. For instance, the overexpression of acid CDase 
protected L929 cells against TNF-induced apoptosis [47], while its upregulation in 
prostate cancer cells conferred resistance to radiation [48], suggesting that acid CDase 
overexpression is a characteristic feature of more advanced and aggressive prostate 
cancers. In accordance with these results, inhibition of acid CDase by a ceramide 
analogue, B13, induced apoptosis in cultured human colon cancer cells, and prevented 
liver metastases in vivo [49], whereas its genetic down regulation by small interfering 
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RNA (siRNA) or the administration of the small molecule acid CDase inhibitor, 
LCL385, sensitized PPC-1 cells to radiation and significantly decreased tumor 
xenograft growth [48]. Noteworthy, this mechanism of ceramide elimination may play a 
relevant role in the resistance of human liver cancer cells against chemotherapy. In this 
regard, daunorubicin (DNR) activated acid CDase post-transcriptionally in human 
(HepG2 cells) or mouse (Hepa1c1c7) hepatoma cell lines as well as in primary cells 
from murine liver tumors, but not in cultured healthy mouse hepatocytes [41]. In 
addition, acid CDase silencing by siRNA or pharmacological inhibition sensitized 
hepatoma cells to DNR-induced cell death and reduced tumor growth in murine liver 
tumor xenografts after DNR therapy [41]. Interestingly, the synergistic effect of 
ceramidase inhibitors in combination with DNR administration is not restricted to this 
chemotherapeutic agent or to HCC. For instance, recent reports described the synergism 
between N-(4-hydroxyphenyl) retinamide and acid CDase inhibition in prostate cancer 
cells [50], while acid CDase expression has been shown to modulate the sensitivity of 
melanoma cells to dacarbazine [51].  
Besides the reduction in ceramide levels, acid CDase activation contributes to the 
resistance of cancer cells to chemotherapy by the generation of S1P. S1P is a potent 
antiapoptotic, prosurvival SLs due to a combined mechanism of action including the 
antagonism of ceramide-mediated cell death pathways from inside cells [52,53], as well 
as by activating proliferative pathways from outside the cell via five specific G protein-
coupled S1P receptors (S1PR1-5) [54]. S1P production requires sphingosine generation 
from ceramide following its deacylation by ceramidase, and the resulting sphingosine 
formation is then phosphorylated by sphingosine kinases (SK). Two SK isoforms (SK1 
and SK2) have been described and characterized. Although these forms seem redundant 
in normal cells their specific increase in different tumor cell types has been associated 
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with cancer progression. Particularly, increased levels of the SK1 protein and/or mRNA 
has been reported in stomach, brain, lung, colon or breast cancers, with a correlation 
between SK1 expression and tumor grade or decreased patient survival [54], suggesting 
S1P as potential target to control tumor growth and angiogenesis [55].  
These divergent effects of ceramide and S1P have led to the definition of a ceramide–
S1P rheostat model, whereby the fate of tumor cells is established by the relative levels 
of these bioactive sphingolipids. Consistent with this notion, CDase and/or SK 
antagonism would promote tumor cell death by a dual mechanism involving the 
increase of intracellular ceramides while simultaneously decreasing the antiapoptotic 
pathways induced by S1P. In this regard, and consistent with previous observations in 
HCC following acid CDase inhibition [41], blocking SK activity has been shown 
effective to kill HCC cells [56], and more interestingly, to decrease xenograft tumor 
growth in combination with sorafenib administration. 
Another important mechanism of ceramide elimination is mediated by GCS. 
Glucosylceramide generation from ceramide glycosylation has been also suggested as 
an effective cellular strategy whereby cancer cells become resistant to chemotherapy. In 
fact, pharmacological inhibition or RNA interference of GCS expression has been 
proved useful to potentiate the anticancer activity of several compounds [57,58,59]. In 
addition, GCS activation underlies the resistance of many cancer cells to chemotherapy 
[60,61], indicating that GCS is a key determinant of the multidrug resistance phenotype. 
In spite of the overwhelming evidence of GCS in chemotherapy resistance, there is little 
data involving GCS in the modulation of liver cancer biology and therapy. For instance, 
pharmacological GCS inhibition has been proved of value to increase effectiveness of 
cancer therapy in liver cancer [62]. Although certain chemosensitizing effect of GCS 
inhibitors have been observed in hepatoma cells, other mechanisms unrelated to GCS 
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might have played a role in this respect. For instance, although ceramide is a well-
recognized SLs that promotes cell death, other species derived from GCS may also 
share this function. In this regard, GD3 ganglioside, for which glucosylceramide 
provides the backbone, is a bioactive lipid with a prominent role in liver pathologies 
[63]. Therefore, the regulation of ceramide along with the subsequent GD3 generation 
in the Golgi may constitute an effective measure to control hepatocellular cancer cell 
death. 
Glycosphingolipids: role of the prototype GD3 ganglioside in cell death. 
Alterations in the pattern of glycosphingolipids have been largely reported in tumor 
cells, probably reflecting changes in critical enzymes in this pathway such as that 
observed with GCS expression and activity [64,65]. Taking advantage of this abnormal 
glycosphingolipid content, clinical trials using ganglioside-based vaccines are ongoing 
based on the identification of gangliosides as tumor antigens due to their abundance on 
the plasma membrane of specific tumor cells, such as in melanoma. In general, the 
increase in ganglioside levels in tumor cells is usually restricted to those with lower 
sialic content [66], while more complex gangliosides, such as GD3, are not modified in 
transformed tissues, as it would be speculated based on its pro-apoptotic function.  
Several mechanisms whereby GD3 promotes cell death have been described. In addition 
to the intracellular redistribution of GD3 in response to TNF/Fas leading to 
mitochondrial targeting [67], GD3-mediated NF-κB inhibition is perhaps one of the 
most relevant ones due to the importance of the κB-dependent induction of survival 
programs that antagonize HCC death contributing to the promotion of 
hepatocarcinogenesis. This novel role of GD3 is of particular significance due to the 
identification of NF-κB activation by hypoxia-generated ROS, through a Src-mediated 
tyrosine phosphorylation, described in neuroblastoma and HCC tumor cell lines [68]. In 
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this pathway, hypoxia stimulates mitochondrial-induced ROS generation in complex III 
of the mitochondrial respiratory chain, which in addition to the activation of HIF-1α 
also results in the tyrosine phosphorylation of IκB-α and subsequent release of NF-κB 
DNA binding complexes p52/50 and p50/p50.  Besides activation of survival pathways, 
NF-κB stimulation induces a protective program against oxidative stress including the 
overexpression of Manganese Superoxide Dismutase (MnSOD). Thus, given this central 
role of NF-κB in cancer cell survival, its antagonism by GD3 may be of relevance as a 
novel strategy to curtail neoplasic growth, and particularly, to reduce tumor progression 
in liver cancer [69].  
As alluded above, besides the blockade of NF-κB activation, GD3 also interacts with 
mitochondria, eliciting a burst of ROS due to the targeting of complex III of the 
mitochondrial respiratory chain that induce the loss of mitochondrial membrane 
potential [69,70]. As a consequence, GD3 contributes to the release of apoptogenic 
proteins from the intermembranal space to the cytosol, such as cytochrome c and 
SMAC/Diablo, and activates caspase dependent apoptotic cell death. [67,70,71,72]. Of 
interest, these proapoptotic effects were induced in hepatocarcinoma cells when GD3 
was exogenously administered in combination with anticancer therapy such as 
antracyclines or ionizing radiation [73,74]. Following the exploitation of these 
proapopoptotic features of GD3, it has been recently observed that GD3 synthase 
overexpression sensitized human HCC cells to hypoxia-induced cell death. This 
processed was mediated by stimulation of GD3 from endogenous GM3 resulting in 
enhanced generation of mitochondrial-derived ROS that reduced HCC progression in a 
xenograft model [69]. In addition, mitochondrial trafficking of GD3 has been shown to 
function as a platform where death signals integrate to optimize the function of Bax to 
induce mitochondrial membrane permeabilization and release of apoptogenic factors 
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[75]. Given the multifactorial nature of GD3 in promoting cell death by a dual 
mechanism involving mitochondrial targeting and engagement of the apoptosome while 
disabling survival pathways, these finding illustrate the potential relevance of GD3 in 
cancer cell biology and therapy. However, whether GD3 synergizes with currently used 
therapy in the treatment of HCC such as sorafenib deserves further investigation. 
Liposomal administration of ceramide as a chemosensitizer. 
Consistent with the ability of ceramide to regulate cell death pathways at different 
levels, its forced accumulation may be an effective strategy to increase the efficacy of 
current cancer therapy. However, this approach has to take in consideration that raising 
intratumoral ceramide levels depends on a number of factors, including specific 
characteristics of each cancer cell and the particular alterations of ceramide metabolism 
induced by chemotherapeutic agents. To overcome these potential pitfalls an attractive 
approach is the delivery of ceramide directly to target cells via administration of 
systemic liposomal particles [76,77]. More importantly, pegylated nanoliposomal 
formulations containing ceramide have demonstrated efficacy as anti-cancer therapy 
both in vitro and in vivo [78,79]. Indeed, nanoliposomal C6-ceramide administration has 
been shown to antagonize pro-survival (AKT) and pro-mitogenic (ERK) signaling 
pathways, resulting in reduced markers of microvascularisation/angiogenesis at tumor 
sites [80]. Of particular relevance, the therapeutic outcome of nanoliposomal C6-
ceramide occurred essentially free of toxic collateral effects, being selectively pro-
apoptotic for breast cancer as well as melanomas but not their corresponding normal 
tissues such as normal mammary epithelial cells and melanocytes. Recently, it has been 
shown that administration of nanoliposomal C6-ceramide is effective in treating in vitro 
and in vivo human models of HCC [79]. Besides its direct apoptotic effects towards SK-
HEP-1 cells, systemic administration of ceramide nanoliposomes in mice engrafted with 
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SK-HEP-1 cells reduced tumor vascularisation, and proliferation, induced tumor cell 
apoptosis, decreased phosphorylation of AKT and blocked in vivo tumor growth. These 
studies not only provide evidence that exogenous ceramide delivery may be of value in 
slowing HCC progression but also suggest that liposomal ceramide administration along 
with other chemotherapeutic agents may be an attractive anticancer approach. Of note, it 
has been recently shown that the administration of nanoliposomal ceramide with 
sorafenib synergistically inhibits melanoma and breast cancer tumor development [80], 
providing solid grounds for clinical trials evaluating the efficacy of combining sorafenib 
with nanoliposomal ceramide for the treatment of HCC. 
Sphingolipidomics in HCC treatment. 
As described above, the realm of SLs contains elements with opposing functions in 
terms of cell death regulation, with some promoting apoptotic events such as ceramide 
and ganglioside GD3, while others stimulate cell proliferation and activation of survival 
pathways, including S1P and ceramide 1 phosphate. Hence, from this scenario it 
becomes clear that this diversity of SLs species may be even more complex in 
transformed cells undergoing phenotypic changes towards malignant transformation. 
Although there is growing evidence pointing to a role of SLs in the regulation of cancer 
cell biology, the lack of a detailed description of the alterations in specific SLs species 
in particular cancer types has hampered the use of sphingolipid-based strategies in 
cancer treatment. However, the dawn of technological advancement allowing lipidomic 
analyses in recent years and the establishment of protocols and techniques to quantify 
SLs content of tissue samples [81,82] opens the door to the generation of 
sphingolipidomic pictures of different types of cancer in the near future. The 
determination of distinctive sphingolipidic signatures in specific tumor types will allow 
the development of cancer treatment based on intervention in sphingolipid metabolism 
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[83], while future clinical testing of circulating bioactive sphingolipids in human blood 
may provide important information as specific markers for cancer progression [84].  
Moreover, the identification of specific anticancer compounds in the modulation of SLs 
metabolism in different cancer tissues would be relevant for potential treatments. In the 
case of HCC, this approach would entail the characterization of the SLs signature both 
in HCC tumors and in the adjacent non-tumor tissue. In addition, the sphingolipidomic 
analysis of primary vs metastatic liver tumors would allow the identification of 
characteristic features in each liver tumor that will help in the design of combinatorial 
therapies with chemotherapeutic agents to increase the success of cancer treatments in 
the liver.  
Cholesterol and chronic liver disease leading to HCC 
Cholesterol is a key component of cellular membranes, which plays a crucial role in 
their integrity and function. Cholesterol regulates the permeability between cellular 
compartments and membrane fluidity [85]. Moreover, cholesterol induces membrane 
packing in specific microdomains of the plasma membrane, acting as a platform for 
membrane-associated signaling proteins [86], and induces lateral lipid segregation and 
regulates membrane elasticity. Due to this role in modulating membrane structure and 
function cholesterol levels need to be tightly regulated; in addition, increases in cell 
cholesterol content may be toxic, particularly if redistributed to specific membranes 
bilayers such as mitochondria (see below). Cell requirement for cholesterol is fulfilled 
either by its uptake from nutrients and lipoproteins or by de novo synthesis from acetyl-
CoA in the so-called mevalonate pathway [87]. Cholesterol biosynthesis occurs in all 
mammalian cells, although the pathway operates at higher capacity in the liver and other 
steroidogenic tissues, such as adrenal cortex and reproductive tissues. Cholesterol is 
synthesized at the ER by a complex process involving the proteolytic activation of 
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transcription factor SREBP-2 by a ER-Golgi cross talk that involves the escort from the 
ER to the Golgi of the inmature SREBP-2 form where is processed into its mature form 
by proteases SP-1 and SP-2 [88,89]. The migration of the mature SREBP-2 form to the 
nuclei induces the transcriptional activation of target genes, including HMG-CoA 
reductase, the rate-limiting enzyme in this pathway [90,91]. Although the role of 
cholesterol in pathogenesis has been best recognized in cardiac and brain vascular 
diseases, emerging evidence points to cholesterol as a key factor in several disorders, 
including metabolic liver diseases such as alcoholic (ASH) and nonalcoholic 
steatohepatitis (NASH) [92]. ASH/NASH is an intermediate stage of fatty liver disease 
which can further progress to cirrhosis and HCC. Due to the rising prevalence of obesity 
worldwide, NASH constitutes a global health concern requiring the urgent need for 
more effective therapies. Recent studies indicated the accumulation of free cholesterol 
in obesity and diabetes models, which leads to the nuclear translocation of SREBP-2, 
thus contributing to the transition from steatosis to NASH [93]. Moreover, studies in 
patients with  NASH indicated the stimulation of free cholesterol levels compared with 
those exhibiting simple steatosis, effects that were accompanied by increased expression 
of SREBP-2 and StAR [94], a mitochondrial cholesterol transporting polypeptide (see 
below). Thus, due to the evolution of ASH/NASH into HCC and the expected increase 
of HCC as the end-stage of chronic liver diseases, it is critical to improve the current 
availability of treatment options for HCC.  
Cholesterol has been gradually recognized as a critical emerging player in liver 
diseases, the bulk for this function resides in the small but powerful pool of cholesterol 
in mitochondrial membranes [92]. Compared to other membrane bilayers, mitochondria 
are cholesterol-poor organelles with estimates of 0.5-3% of the total cholesterol pool. 
Despite its low abundance, the mitochondrial cholesterol pool plays significant 
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physiological roles in liver and steroidogenic tissues, acting as a precursor for the 
synthesis of bile acids and steroidogenic hormones, respectively. Although the 
regulation of mitochondrial cholesterol is still poorly understood, significant progress in 
this particular aspect has been made with the characterization of specialized carriers that 
belong to the family of steroidogenic acute regulatory protein StAR, which function not 
only in the delivery of cholesterol from extramitochondrial sources to mitochondria but 
also in the trafficking from the outer membrane to inner membrane for metabolism 
[95,96,97]. In addition to the StAR family, other proteins known to bind cholesterol 
have been recently characterized in the regulation of mitochondrial cholesterol. 
 Although caveolin-1 is best recognized as a protein residing in defined domains of the 
plasma membrane, recent observations indicated that it is also present in other 
membrane bilayers. Indeed, caveolin-1 has been localized in other non-caveolae sites, 
including mitochondria. Pioneering work by Andersson et al using cell fractionation and 
immunoelectron microscopy described the localization of caveolin-1 in mitochondria of 
epithelial cells, including hepatocytes [98]. While these findings were largely ignored, a 
recent report confirmed the original observations of Andersson et al, validating the 
presence of caveolin-1 in hepatic mitochondria [99]. Moreover, Mastrodonato et al 
reported enhanced levels of caveolin-1 in mitochondria from steatotic livers, indicating 
that increased hepatic cholesterol traffics to mitochondria where it distributes between 
the outer and inner membrane. Consistent with these findings we have recently 
observed that deficiency of caveolin-1 leads to increased mitochondrial cholesterol 
levels both in hepatic and brain mitochondria [100]. Moreover, caveolin-1 does not 
distribute homogeneously in hepatic mitochondria but partitions largely in detergent 
insoluble fractions in colocalization with markers defining mitochondria associated 
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membranes (MAM) (Fernandez et al, manuscript in preparation), consistent with recent 
observations in brain mitochondria [101]. 
Despite its small content, the mitochondrial pool of cholesterol has been revealed as an 
important player in different diseases, playing a prominent role in neurodegeneration 
and hepatopathies [93, 94, 102,103,104]. Of particular relevance to liver diseases, using 
nutritional and genetic models of hepatic steatosis, it has been shown that mitochondrial 
cholesterol loading sensitizes to TNF- and Fas-induced steatohepatitis, increasing the 
hepatocellular susceptibility to cytokines via mitochondrial glutathione (mGSH) 
depletion [103]. In a similar fashion, the diminished mitochondrial capacity to cope 
with reactive oxygen species seems to be responsible for the enhanced sensitivity to 
liver damage during ischemia/reperfusion, as observed in murine steatotic livers that 
presented mitochondrial accumulation of cholesterol [104]. Therefore, if mitochondrial 
cholesterol is a critical factor contributing to the progression of liver diseases, its 
regulation may be of clinical significance in the early phases of HCC development. 
Based on their ability to modulate mitochondrial cholesterol trafficking, caveolin-1 and 
StAR may constitute novel targets for intervention to control cholesterol accumulation 
in mitochondria and hence in the progression of chronic liver diseases. However, their 
specific contribution in mitochondrial cholesterol regulation would be opposite, with 
caveolin-1 preventing while StAR favoring mitochondrial cholesterol loading (Figure 
3). This model is consistent the phenotype observed in caveolin-1 knockout mice [100] 
while StAR silencing abrogates mitochondrial cholesterol accumulation in hepatocytes 
[105]. 
In addition to the unphysiological enrichment of mitochondria in cholesterol during 
liver disease progression and HCC, another level of deregulation of cholesterol 
homeostasis lays in the de novo synthesis of cholesterol in cancer cells (Figure 4). One 
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essential mechanism to control de novo cholesterol synthesis is the feedback and 
transcriptional control of HMG-CoAR by cholesterol. HMG-CoAR resides in the ER 
linked via its N-terminal domain and sterol and nonsterol end products of the 
mevalonate pathway control HMG-CoAR, to allow for continued production of 
essential nonsterol isoprenoids. A fundamental mechanism for feedback control 
involves the rapid degradation of HMG-CoAR, mediated by Insig-1 and Insig-2, two 
ER-resident proteins. Accumulation of sterols in ER membranes triggers binding of the 
membrane domain of HMG-CoAR to a specialized protein, which carries a membrane-
anchored ubiquitin ligase, gp78, which signals the ubiquitination of the reductase and its 
proteasomal degradation [106,107]. Another mechanism regulating cholesterol 
synthesis is the availability of oxygen. Most of the oxygen required in this process is 
involved in the sequential removal of three methyl groups of lanosterol, resulting in 
zymostenol. Recent findings have reported that hypoxia stimulates degradation of 
HMG-CoAR through both accumulation of lanosterol and HIF-1α-mediated Insigs 
induction [108].  
Given these regulatory factors of the de novo cholesterol synthesis, the recognized 
accumulation of cholesterol during HCC development [109] seems a conundrum. As a 
critical component of membrane bilayers, cholesterol accumulates in HCC to support 
the rate of cell proliferation and formation of new membrane bilayers during tumor 
growth and this response occurs with the resistance of HMG-CoA reductase to 
proteasomal degradation. Moreover, since hypoxia is a key feature of solid tumors due 
to abnormal vessels architecture, cholesterol synthesis in growing HCC tumors seems 
insensitive to the limited oxygen availability. Further understanding of these abnormal 
features may be key to design specific armamentarium to disrupt the reliance of 
growing HCC on cholesterol requirement to promote tumor growth. As described 
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below, much of this dependence on cholesterol in hepatocarcinogenesis is via its 
preferred trafficking to mitochondria.  
Mitochondrial cholesterol in HCC treatment 
As detailed above, cancer cells exhibit critical metabolic changes regarding the 
cholesterol homeostasis, as best illustrated by the ability of solid tumors to synthesize 
cholesterol under hypoxia, which contrasts with the physiological requirement for 
oxygen in the transformation of lanosterol into cholesterol via 9 redox reactions. In 
addition to this continued cholesterol synthesis in growing tumor cells, we have recently 
observed the stimulation of cholesterol trafficking to mitochondria from HCC cells. 
Since its description almost 30 years ago in heterotopic Morris hepatoma xenografts in 
Buffalo rats [110], the mitochondrial enrichment in cholesterol has been viewed mainly 
as a key factor underlying the mitochondrial dysfunction characteristic of cancer cells 
[109]. Indeed, in situ cholesterol enrichment in hepatic mitochondria impairs the 
acceptor control ratio, oxidative phosphorylation and the function of specific MPT 
components. For instance, cholesterol loading in rat liver mitochondria prevented 
atractyloside to induce the m-conformational change in ANT to cause MPT and release 
proapoptotic proteins into the cytosol [111]. 
However, in addition to this putative effect of cholesterol in the regulation of 
mitochondrial function of cancer cells, we focused on the role of mitochondrial 
cholesterol in chemotherapy sensitivity and cell death regulation. Established human, 
rat and mouse HCC exhibit increased mitochondrial cholesterol levels with respect to 
non-tumor mitochondria from human, rat or mouse liver [112], consistent with previous 
studies in solid hepatoma mitochondria compared with host liver [110, 113,114,115]. Of 
interest, the up-regulation of mitochondrial cholesterol content in HCC correlates with 
increased expression of SREBP-2 and HMG-CoA reductase, validating the cholesterol 
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deregulation of cancer cells. In addition to these changes, HCC cells exhibit increased 
StAR mRNA levels, which correlate with the degree of mitochondrial cholesterol 
loading. This selective trafficking of cholesterol to mitochondria reduces the sensitivity 
to chemotherapy agents acting via MPT. For instance, while rat and human HCC 
become resistant to lodinamide or daunorubicin-mediated mitochondrial membrane 
permeabilization and cytochrome c release [112], these cells are sensitive to 
bafilomycin A, an inhibitor of the vacuolar type H+-ATPase that impairs lysosomal 
function and promotes apoptosis independently of mitochondrial membrane 
permeability. Moreover, StAR silencing following siRNA treatment sensitized human 
and rat HCC to chemotherapy, demonstrating that the accumulation of mitochondrial 
cholesterol protects HCC against cell death by disabling the ability of mitochondria to 
undergo MPT and mitochondrial membrane permeabilization.  
Since cholesterol is known to regulate membrane properties [85,86], we hypothesized 
that the mechanisms of the mitochondrial cholesterol-induced resistance of HCC to 
chemotherapy might imply alterations in membrane dynamics. Indeed, isolated 
mitochondria from HepG2 or H35 hepatoma cells exhibit higher order, which is 
reversed by cholesterol extraction with methyl-β-cyclodextrine or fluidization by the 
fatty acid derivative A2C, resulting in increased MPT and release of cytochrome c in 
response to Ca2+ loading, superoxide anion of active Bax. Thus, these data indicate that 
mitochondrial cholesterol loading in HCC is antiapoptotic and protects HCC 
mitochondria against membrane permeabilization by increasing membrane order. To 
further confirm this possibility, similar data was observed in large unilamelar vesicles 
(LUVs) of defined lipid composition entrapping fluorescent dextrans following active 
Bax exposure. Quite interestingly, while Bax efficiently released fluorescent dextrans 
into the medium in control LUVs, cholesterol-containing LUVs were resistant to Bax-
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mediated permeabilization [112], reproducing the effects observed in mitochondria from 
HCC. Moreover, the data indicated that cholesterol reduced the capacity of Bax to 
penetrate into the membrane, which is considered a critical step in Bax activation. Thus, 
through modulation of membrane order and curvature stress, cholesterol regulates the 
ability of mitochondria to become permeabilized in response to a wide range of 
proapoptotic agents including chemotherapy, protecting HCC against cell death. 
Moreover, observations in HeLa cells treated with U18666A, which results in 
mitochondrial cholesterol loading, indicated a delayed release of Smac/DIABLO and 
cytochrome c, as well as in Bax oligomerization and partial protection against stress-
induced apoptosis [116]. These results in cervix cancer cells suggest that the influence 
of mitochondrial cholesterol on tumor progression observed in HCC is not exclusive for 
liver cancer, suggesting that the abnormal homeostasis of cholesterol, in particular its 
mitochondrial trafficking, may be a general key feature of carcinogenesis and a novel 
target for therapeutic intervention. In line with this possibility, treatment of HCC with 
lovastatin both in vitro and in vivo reduced tumor cholesterol content, including the 
mitochondrial pool, resulting in increased susceptibility to chemotherapy and reduced 
tumor growth [112]. Although statins are known to regulate carcinogenesis via 
mechanisms independent on the cholesterol lowering effects [117], our findings add a 
novel mechanism of action of statins by indirectly regulating the trafficking of 
mitochondrial cholesterol.  
 
 
Morales et al, ACA-MC 
 
25
CONCLUDING REMARKS 
HCC is one of the leading causes of cancer-related deaths in the world, and constitutes 
the end stage of chronic liver diseases. Current available therapy is limited and 
unfortunately effective treatment can only be offered to a selected group of patients. 
Given the progression of metabolic liver diseases such as ASH/NASH towards HCC 
and their association with obesity and type 2 diabetes, there is an urgent need to increase 
the therapeutic options for patients suffering HCC. In addition to genetic studies linking 
the pattern of gene expression with prognosis and disease recurrence, a better 
understanding of the molecular pathways contributing to HCC may pave the way for 
novel therapeutic avenues. HCC is an extremely complex and heterogeneous disease 
whose progression is often determined by the initial cause or insult leading to 
hepatocellular death and uncontrolled proliferation. In addition to the genetic and 
epigenetic reprogramming occurring in HCC, abnormal signaling pathways and lipid 
homeostasis contribute as well to the progression of HCC. Consistent with their crucial 
roles in membrane structure and function, cholesterol and SLs have emerged as key 
lipid mediators that regulate a number of cellular processes, some of which are essential 
to neoplasic transformation and tumor growth, such as differentiation, proliferation and 
cell death. In this regard, recent evidence and current studies validate a role for altered 
cholesterol and SLs metabolism as a critical metabolic component contributing to key 
aspects of HCC, including cell death and chemotherapy resistance. Of particular 
relevance is the realm of SLs, which encompass not only key mediators promoting cell 
death (e.g. ceramide and ganglioside GD3) but also other derivatives (e.g. S1P) that 
sustain cell survival and proliferation. While many of the current drugs used to treat 
solid tumors including HCC generate proapoptotic ceramide, a common strategy of 
advanced cancers is the reprogramming and induction of antiapoptotic SLs to 
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antagonize the therapeutic effect of the former. In addition to this scenario, HCC exhibit 
abnormal cholesterol metabolism and homeostasis, and undergo an unphysiological 
trafficking towards mitochondria to shield the outer membrane to resist 
permeabilization when challenged with therapeutic drugs. Thus, a better understanding 
of the metabolic disturbances of ceramide and cholesterol metabolism may prove useful 
to design novel and more effective therapeutic combinations, which hopefully will be 
available soon in the near future to better manage HCC patients. For instance statins, 
already taken by a high number of patients to control cardiovascular events may be also 
of potential interest to control HCC progression, particularly in association with other 
current chemotherapies. Besides statins, inhibitors of other enzymes in cholesterol 
synthesis, such as squalene synthase, may specifically prevent cholesterol without 
interfering with isoprenoid synthesis, or even drugs that prevent cholesterol absorption, 
may be of potential use in HCC [118]. In addition, to control ceramide/cholesterol 
metabolism could improve the management of the progression of metabolic liver 
diseases ASH/NASH and ultimately influence the incidence of HCC. 
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ABBREVIATIONS 
ASH: alcoholic steatohepatitis 
ASMase: acid sphingomyelinase 
CDase: ceramidase 
Cer: ceramide 
CerK: ceramide kinase 
CerS: ceramide synthase 
CERT: ceramide transport protein  
DNR: daunorubicin 
ER: endoplasmic reticulum 
FA: fatty acid 
GCS: glucosylceramide synthase 
GlcCer: glucosylceramide 
GSL: glycosphingolipids 
GSH: glutathione 
HCC: hepatocellular carcinoma  
LUV: large unilamelar vesicles 
MPT: mitochondrial permeability transition 
NASH: non-alcoholic steatohepatitis 
NSMase: neutral sphingomyelinase  
ROS : reactive oxygen species 
S1P: sphingosine 1 phosphate 
SK: sphingosine kinase 
SL: sphingolipid 
SMase: sphingomyelinase  
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SMS: sphingomyelin synthase 
SPT: serine palmitoyl transferase 
SREBP: sterol regulatory element-binding protein 
StAR: steroidogenic acute regulatory protein 
VLCFA: very long chain fatty acid 
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TABLE 1. 
Name Tissue mRNA expression profile 
Acyl chain-length 
specificity 
CerS1 Brain, skeletal muscle, testis  C18 
CerS2 Kidney, liver  C20, C22, C24, C26 
CerS3 Testis, skin  C22, C24, C26 
CerS4 skin, leukocytes, heart, liver  
C18, C20, C22, C24, 
C26 
CerS5 Low expression in all tissues  C16 
CerS6 Low expression in all tissues  C14, C16 
 
Human ceramide synthases expression. All six enzymes (CerS1-6) proceed from 
different genes, have dissimilar pattern of tissue expression and display specific 
activities towards the length of acyl-CoA substrates. Main tissues of mRNA expression 
and acyl chains with higher affinity for each individual CerS are shown.   
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FIGURE LEGENDS 
Figure 1. Chemical structure of ceramide. After the condensation of serine with 
palmitoyl-CoA, by the action of the serine palmitoyl transferase (SPT), the long-chain 
base sphinganine is attached to fatty acyl CoAs of different length as an amide linkage 
producing ceramide (C16 depicted) throught ceramide synthase (CS) activity. Although 
ceramide is the prototype of SLs, there are other modifications in the structure of the 
long-base chain other than the desaturation as shown, and include the hydroxylation in 
carbon 4, yielding phytosphingosine or phosphorylation in the hydroxyl group, yielding 
ceramide 1 phosphate (not shown here). 
Figure 2. Schematic representation of main cellular pathways involved in ceramide 
metabolism in the liver. 
Figure 3. Scheme illustrating the regulation of mitochondrial cholesterol during HCC. 
Although the levels of cholesterol in mitochondria are low, during HCC cholesterol 
accumulates in mitochondrial membranes. Both caveolin-1 and StAR regulate 
cholesterol trafficking in a dynamic and bidirectional fashion. Data is consistent with 
caveolin-1 negatively regulating mitochondrial cholesterol as opposed to StAR which 
positively moves cholesterol not only towards mitochondrial membranes but also 
between the outer and the inner membrane. 
Figure 4. Simplified representation of main enzymatic reactions involved in cholesterol 
biosynthesis in mammalian cells. Statins prevent mevalonate formation from HMG-
COA, while inhibitors under the sterol branch of Farnesyl-PP, such as squalene 
synthase, may block cholesterol synthesis without perturbing isoprenoid production. 
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